Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0JMIR Medical Informatics

Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review

4 affiliations
  1. 1Information Technologies Institute, Centre for Research and Technology Hellas, 6th Km Charilaou-Thermi, Thessaloniki, 57001, Greece, +306973900849
  2. 2Institute of eHealth, FH JOANNEUM GmbH – University of Applied Sciences, Graz, Austria
  3. 3Vaccines Research Department, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain
  4. 4BBMRI-ERIC, Graz, Austria

Abstract

Background: Decentralized clinical trials (DCTs) are reshaping clinical research through digital technologies such as telemedicine, mobile apps, wearable and sensor-based tools, and digital platforms. These technologies can support participation, safety, accessibility, data collection, monitoring, and trial operations. Although DCT adoption accelerated during the COVID-19 pandemic, the commercial technology landscape remains fragmented and continues to evolve rapidly. There is limited understanding of how commercial technologies align with operational activities across the DCT life cycle. The Basic Building Block (BBB) framework used in this review divides the DCT life cycle into 7 functional areas: setup and design; recruitment and enrollment; data acquisition and processing; operation and coordination; patient engagement; intervention and follow-up; and close-out and reporting.

Objective: This scoping review aimed to map commercial technologies supporting DCT operations and assess their availability and functional alignment with clinical trial processes.

Methods: A scoping review of commercial technologies was conducted from January 2024 to June 2025 to update a previous 2020 technology scan, with a search rerun in June 2026 for update and verification purposes. Eligible technologies were commercially available, publicly documented, and relevant to at least 1 BBB. The review was reported in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews), with search reporting guided by PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Literature Search extension) where applicable. Seven 2-person reviewer groups reassessed previously identified technologies and identified additional technologies by analyzing publicly available English-language sources, including vendor and company websites, product documentation, public reports, case studies, company announcements, and relevant academic literature. Technologies were categorized by BBB coverage, classified as single-BBB if they supported 1 BBB and multiple-BBB if they supported more than 1 BBB, and analyzed using a co-occurrence matrix.

Results: The final catalog included 329 commercial technologies, spanning the DCT life cycle. Most were multiple-BBB technologies, with 293 multiple-BBB and 36 single-BBB technologies. Operation and coordination was the most frequently covered BBB (n=220), followed by data acquisition and processing (n=212), setup and design (n=189), patient engagement (n=165), close-out and reporting (n=125), intervention and follow-up (n=122), and recruitment and enrollment (n=120). The strongest co-occurrence pairings were data acquisition and processing with operation and coordination; setup and design with operation and coordination; and setup and design with data acquisition and processing. The weakest pairings involved close-out and reporting with intervention and follow-up, with recruitment and enrollment, and with patient engagement.

Conclusions: This scoping review provides an updated structured mapping of 329 commercial technologies supporting DCT operations. By combining a commercial technology scan with the BBB framework, the review quantifies functional coverage and co-occurrence across the DCT life cycle. The findings can support technology selection for decentralized and hybrid trials while highlighting operational areas where technology coverage seems to be less commonly combined.

Related

  1. Application of spectroscopic and multispectral imaging technologies on the assessment of ready-to-eat pineapple quality: A performance evaluation study of machine learning models generated from two commercial data analytics tools
    Evanthia Manthou, Sergio-Llaneza Lago, Evaggelos Dagres +5
    Computers and Electronics in AgriculturePeer-reviewedLicence not stated38 citedGeneral biologyGeneral chemistryHAL
  2. Beyond Connected Diabetes Technologies: Toward an Orchestrated Digital Healthcare Ecosystem for Diabetes Care
    Pei-Ju Li, Yau-Jiunn Lee, Hui-Chun Hsu
    NutrientsPeer-reviewedCC BY 4.0NutritionCrossref
  3. Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs
    Marco Schito, Stacey Coe, Jaime Seltzer +7
    Frontiers in public healthPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
  4. Adoption of ‘decentralized’ clinical trial terminology: a systematic review of self-identified decentralized clinical trials
    Annie Wright, Otavio Berwanger, Shwetha Rajaram +3
    TrialsPeer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
  5. Facing far forward: Mental health in large-scale combat operations
    Tim Hoyt, Amy B. Adler
    Military PsychologyPeer-reviewedLicence not statedFull text1 citedPsychiatry & mental healthPMC
BibTeX
@article{mpaltadoros2026quantifying,
  title = {{Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review}},
  author = {Lampros Mpaltadoros and Simone Huber and Thanos G Stavropoulos and Bianca Buchgraber-Schnalzer and Jaime Fons-Martínez and Carlos Murciano-Gamborino and Baptiste Alcalde and Lina Pérez-Breva and Spiros Nikolopoulos and Ioannis Kompatsiaris and Sten Hanke},
  journal = {JMIR Medical Informatics},
  year = {2026},
  month = nov,
  doi = {10.2196/86011},
  url = {https://doi.org/10.2196/86011},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Quantifying the Digital Ecosystem of Commercial Technologies for Decentralized Clinical Trial Operations: Scoping Review
AU  - Lampros Mpaltadoros
AU  - Simone Huber
AU  - Thanos G Stavropoulos
AU  - Bianca Buchgraber-Schnalzer
AU  - Jaime Fons-Martínez
AU  - Carlos Murciano-Gamborino
AU  - Baptiste Alcalde
AU  - Lina Pérez-Breva
AU  - Spiros Nikolopoulos
AU  - Ioannis Kompatsiaris
AU  - Sten Hanke
PY  - 2026
DA  - 2026/11/12
JO  - JMIR Medical Informatics
DO  - 10.2196/86011
UR  - https://doi.org/10.2196/86011
AB  - Background: Decentralized clinical trials (DCTs) are reshaping clinical research through digital technologies such as telemedicine, mobile apps, wearable and sensor-based tools, and digital platforms. These technologies can support participation, safety, accessibility, data collection, monitoring, and trial operations. Although DCT adoption accelerated during the COVID-19 pandemic, the commercial technology landscape remains fragmented and continues to evolve rapidly. There is limited understanding of how commercial technologies align with operational activities across the DCT life cycle. The Basic Building Block (BBB) framework used in this review divides the DCT life cycle into 7 functional areas: setup and design; recruitment and enrollment; data acquisition and processing; operation and coordination; patient engagement; intervention and follow-up; and close-out and reporting.  Objective: This scoping review aimed to map commercial technologies supporting DCT operations and assess their availability and functional alignment with clinical trial processes.  Methods: A scoping review of commercial technologies was conducted from January 2024 to June 2025 to update a previous 2020 technology scan, with a search rerun in June 2026 for update and verification purposes. Eligible technologies were commercially available, publicly documented, and relevant to at least 1 BBB. The review was reported in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews), with search reporting guided by PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Literature Search extension) where applicable. Seven 2-person reviewer groups reassessed previously identified technologies and identified additional technologies by analyzing publicly available English-language sources, including vendor and company websites, product documentation, public reports, case studies, company announcements, and relevant academic literature. Technologies were categorized by BBB coverage, classified as single-BBB if they supported 1 BBB and multiple-BBB if they supported more than 1 BBB, and analyzed using a co-occurrence matrix.  Results: The final catalog included 329 commercial technologies, spanning the DCT life cycle. Most were multiple-BBB technologies, with 293 multiple-BBB and 36 single-BBB technologies. Operation and coordination was the most frequently covered BBB (n=220), followed by data acquisition and processing (n=212), setup and design (n=189), patient engagement (n=165), close-out and reporting (n=125), intervention and follow-up (n=122), and recruitment and enrollment (n=120). The strongest co-occurrence pairings were data acquisition and processing with operation and coordination; setup and design with operation and coordination; and setup and design with data acquisition and processing. The weakest pairings involved close-out and reporting with intervention and follow-up, with recruitment and enrollment, and with patient engagement.  Conclusions: This scoping review provides an updated structured mapping of 329 commercial technologies supporting DCT operations. By combining a commercial technology scan with the BBB framework, the review quantifies functional coverage and co-occurrence across the DCT life cycle. The findings can support technology selection for decentralized and hybrid trials while highlighting operational areas where technology coverage seems to be less commonly combined.
SN  - 2291-9694
ER  -